Innovation System Review with Charlie Day
Set to play an instrumental role in advancing Australian innovation, Charlie Day is tasked with developing a strategy to build a robust and effective innovation system by 2030. Delivering a plenary presentation at AusBiotech 2017, Charlie, the Chief Executive Officer of Innovation and Science Australia (ISA), will provide an update on the Innovation, Science and Research (ISR) System and strategic plan development.
Read Charlie Day names his top challenges as CEO of Innovation and Science Australia from the Australian Financial Review.
Inventing supply chains with Tim Oldham
How can supply chain development help create cures in the twenty-first century? In his plenary presentation, Tim Oldham will examine supply chains from a biotech perspective and discuss its implications for product development. Tim is the Chief Executive Officer of Cell Therapies, which is a recognised leader in manufacturing and distribution of cell-based therapies.
Read more about Cell Therapies.
Australian biotech sector performance and drug development companies, with Peter Molloy
Peter Molloy is the CEO of Race Oncology Ltd. In addition, since 2014, he has been an Adjunct Teaching Fellow at Swinburne University of Technology, where he has given guest lectures on biotechnology strategy and commercialisation and recently published a paper on the challenges of strategic planning for biotech firms. He has also undertaken research into the performance of the Australian biotech sector from 2003-2016, focussing on drug development biotech firms. The research provides the first comprehensive, long-term, performance analysis of the Australian drug development biotech sector and in this session, he will share the results of that research, prior to their future publication. He will also address key questions such as: how ‘biotech’ firms are defined, how value creation is measured, and what the value creation drivers and impediments are for Australian firms. It promises to be an interesting and enlightening plenary session.
Drug development in fast forward: value-focused drug development strategies of the future, with Dr Craig Rayner
Dr Craig Rayner is the President of d3 Medicine and has more than 15 years of drug development experience. His past appointments include leadership roles in Clinical Pharmacology and Early development (Roche), Clinical Development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) and as an academic researcher in clinical pharmacology and infectious disease research (Monash University).
Dr Rayner has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities. He holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), and is broadly published in clinical pharmacology and also infectious diseases.
Stay tuned for further updates to the AusBiotech 2017 national conference program. A draft will be available in May.
We gratefully acknowedge our session partners: